Article contentDISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and a ...

Core Viewpoint - The article discusses the completion of summer exploration programs by GoldHaven Resources Corp, highlighting the company's ongoing efforts in mineral exploration and development [1]. Group 1: Company Overview - GoldHaven Resources Corp has recently completed its summer exploration programs, which are crucial for advancing its mineral projects [1]. - The company is focused on exploring gold and other mineral resources, indicating a strategic emphasis on valuable commodities [1]. Group 2: Technical Information - The technical information disclosed in the article has been reviewed and approved by qualified professionals, ensuring credibility in the exploration results [1]. - The Copeçal Technical Report identifies Jean-Marc Lopez as the Qualified Person responsible for the report, adding a layer of expertise to the findings [1].

Core Insights - The market is shifting from speculative growth to essential infrastructure, focusing on critical needs such as data integrity, energy security, and biological resilience [1][2] - Companies that provide essential services are gaining attention as institutional capital accumulates in these areas, contrasting with retail investors chasing speculative opportunities [2] Quantum Security Encryption Corp. (QSE) - QSE has rebranded from Scope Technologies to focus on quantum defense, launching QSE-Chat, a quantum-resilient mobile application for enterprise and government use [3][4] - The company employs post-quantum cryptographic algorithms to secure data against future quantum computing threats, positioning itself as critical infrastructure for the information age [5] Aleen Inc. - Aleen is transforming the wellness market by allowing users to own their biometric data rather than being mere donors [7][10] - The company has developed a Smart Analytics feature that provides actionable insights from biometric data without crossing into medical diagnosis [8][9] Rush Gold Corp. - Rush Gold is positioned as a high-grade silver play, with historical sampling at its Legal Tender Property returning grades as high as 1,875 grams per tonne silver [12][13] - The company benefits from the dual role of silver as both a monetary metal and a critical industrial input, particularly in green infrastructure [13][14] Homeland Uranium - Homeland Uranium is focused on energy independence, with a defined resource estimate of 8.85 million pounds of uranium at its Coyote Basin project in Colorado [18][19] - The company aims to validate known mineralization in a secure jurisdiction, addressing the urgent need for domestic nuclear fuel supply [19] Avant Technologies Inc. - Avant Technologies has pivoted into cell-based therapy, focusing on encapsulated cell treatments for diabetes and securing rights to Klotho-producing cells for longevity [21][23] - The company targets significant healthcare markets, positioning itself as a critical player in human longevity and health optimization [24]

Core Insights - Avant Technologies Inc. and Austrianova have launched a joint venture named Klothonova LLC, focusing on the Klotho development program aimed at creating cell-based therapies for age-related diseases and promoting longevity [1][4] - The Klotho protein is recognized for its anti-aging properties, and the global market for cell-based therapies is projected to reach $44 billion [4][5] Research and Development - The initial phase of the program has successfully generated genetically modified human cells that overproduce the Klotho protein, demonstrating the feasibility of using encapsulated cells for continuous production [2][3] - Austrianova is preparing for the next stage by ensuring compliance with GMP standards and conducting necessary documentation for preclinical and clinical studies [3][4] Joint Venture Details - Klothonova is a Nevada-based entity equally owned by Avant and Austrianova's affiliate, SGAustria Pte. Ltd., established through a joint venture agreement signed in September 2025 [4] - The collaboration leverages Austrianova's cell encapsulation technology and Avant's innovative vision, positioning the joint venture for success in the biotechnology sector [4]

Core Insights - Avant Technologies Inc. is shifting its business model to focus on strategic partnerships through joint ventures and licensing agreements to enhance treatments for chronic and age-related conditions [1][2] - The company has applied for a corporate name change to better reflect its commitment to biotechnology collaborations aimed at improving health and longevity [1] Business Strategy - Avant is positioning itself at the forefront of collaborative biotech innovation by identifying promising cell lines globally and forming alliances with leading biotech companies, scientists, and clinicians [2][3] - The new partnership-driven model allows Avant to share development costs and risks, leveraging complementary expertise to accelerate the creation of groundbreaking therapies targeting diseases such as diabetes, Alzheimer's, heart disease, cancer, and kidney disease [2][3] Key Collaborations - Avant's partnerships include working with biotech firms specializing in genetically modified cell lines and a global cell-encapsulation technology company to ensure the efficacy and safety of therapeutic applications [3] - The first joint venture with Ainnova Tech, Inc. utilizes an advanced Vision AI platform for non-invasive diagnostics related to diabetes complications [4] - A new joint venture focuses on developing a cell line therapy that produces the Klotho protein, which plays a crucial role in aging and disease processes [4] Innovation and Development - The ecosystem of joint ventures enables Avant to bridge the gap between disease detection and targeted treatment, fostering advancements in personalized medicine [5] - The company aims to create a robust pipeline for identifying and treating serious illnesses through its collaborative efforts [4][5]

Accessibility StatementSkip Navigation LAS VEGAS, Sept. 18, 2025 /PRNewswire/ -- Avant Technologies Inc. (OTCQB: AVAI) ("Avant" or the "Company"), a Nevada-based corporation, and Austrianova (SGAustria Pte. Ltd.), a Singapore-based biotechnology leader, today announced the formation of a Joint Venture and License Agreement to establish Klothonova, Inc., a new Nevada corporation focused on pioneering cell-based therapies utilizing encapsulated Klotho-producing cells. Continue Reading Avant Technologies Logo ...

Core Insights - Avant Technologies Inc. and Ainnova Tech, Inc. are collaborating on a clinical trial for the Vision AI platform aimed at early detection of diabetic retinopathy [1][4] - Ainnova is refining its patient recruitment strategy to include approximately 1,000 multiethnic patients, focusing on community clinics rather than specialized centers [2][3] - The partnership with Fortrea, a recognized Contract Research Organization, is expected to enhance the quality and efficiency of the clinical study [4][5] Company Overview - Avant Technologies Inc. is an emerging technology company focused on healthcare solutions utilizing artificial intelligence and biotechnology [7] - Ainnova Tech, Inc. is a healthtech startup dedicated to leveraging AI for early disease detection, with a specific focus on preventing blindness related to diabetes [6] Clinical Trial Details - The clinical study will take place at 8-10 sites across the U.S., targeting a diverse patient population to ensure the data reflects real-world scenarios [2][3] - The study's design aims to support the FDA 510(k) submission, which is crucial for regulatory approval and market entry [4][5] Strategic Importance - The success of the clinical trial is vital for Ainnova's technology portfolio, particularly for entering the U.S. market, which presents significant commercial potential [5]